Skinning up? Sinclair IS raises £9m for Valeant derma rights
This article was originally published in Scrip
Sinclair IS Pharma is paying £9.0 million up front for distribution rights in Western Europe to certain products belonging to Valeant Pharmaceuticals that together generated revenues of £9.1 million in 2011 in that territory. Sinclair IS will also make additional sales-based royalty payments over the life of the exclusive 100 year agreement.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.